olaparib and Adenocarcinoma

olaparib has been researched along with Adenocarcinoma* in 1 studies

Other Studies

1 other study(ies) available for olaparib and Adenocarcinoma

Article	Year
Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib. Journal of medicinal chemistry, 2020, 03-12, Volume: 63, Issue:5 Synthetic lethality is an innovative framework for discovering novel anticancer drug candidates. One example is the use of PARP inhibitors (PARPi) in oncology patients with Topics: Adenocarcinoma; Antineoplastic Agents; BRCA2 Protein; Cell Line, Tumor; DNA Damage; Drug Discovery; Drug Synergism; Homologous Recombination; Humans; Models, Molecular; Pancreatic Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Interaction Maps; Rad51 Recombinase; Small Molecule Libraries; Synthetic Lethal Mutations	2020

Article

Year

Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib.

Journal of medicinal chemistry, 2020, 03-12, Volume: 63, Issue:5

Synthetic lethality is an innovative framework for discovering novel anticancer drug candidates. One example is the use of PARP inhibitors (PARPi) in oncology patients with

Topics: Adenocarcinoma; Antineoplastic Agents; BRCA2 Protein; Cell Line, Tumor; DNA Damage; Drug Discovery; Drug Synergism; Homologous Recombination; Humans; Models, Molecular; Pancreatic Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Interaction Maps; Rad51 Recombinase; Small Molecule Libraries; Synthetic Lethal Mutations

2020